How to interpret the Oncotype DX® test results
For your patients with HR+, HER2-, early-stage, invasive breast cancer
The Oncotype DX Breast Recurrence Score® report provides three pieces of information to guide adjuvant chemotherapy treatment decisions for node-negative and node-positive, hormone receptor-positive, HER2-negative, early-stage breast cancer patients.
3 pieces of information provided by the test
1
The Recurrence Score® result
This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score result is used to predict the risk of the breast cancer returning at a distant site, distant recurrence and whether chemotherapy may help reduce the risk.1–6
2
Distant recurrence risk at 9 yearsa
This percentage shows the individualized risk of distant recurrence within 9 years based on the Recurrence Score result when treated with hormonal therapy alone for 5 years.1,4-5
3
Group average absolute chemotherapy benefita
This percentage indicates the benefit expected from adding chemotherapy to hormonal therapy in order to reduce the risk of breast cancer recurrence or death for the Recurrence Score risk group.2-3,4,6
-
Further Understanding the Results: Node-Negative Patients
-
Further Understanding the Results: Node-Positive Patients
Support Materials
Download clinician-to-patient discussion guides
-
ABBREVIATIONS
-
REFERENCES